Showing posts with label Rheumatoid Arthritis. Show all posts
Showing posts with label Rheumatoid Arthritis. Show all posts

Tuesday, August 9, 2016

Body Suppresses Inflammation During Sleep at Night Time

Concept: People have been suffering from morning stiffness for ages. The common feeling is that we sleep absence of pain, but when we wake up things just starting going bad to worse. Though many theories were placed to explain the phenomena of morning stiffness but none is able to explain the observation completely.



In a new research it is proved that biological clock of human body regulated inflammation especially during night sleep. With the help of a protein named Cryptochrome, the body actively represses inflammatory pathways within the affected limbs during the night.

Observations: Researchers from the field of inflammatory diseases have common observations such as:
a: There is strong diurnal variation in the symptoms and severity of chronic inflammatory diseases, such as rheumatoid arthritis.
b: Disruption of the circadian clock is an aggravating factor associated with a range of human inflammatory diseases.

Methodology: In order to investigate the mechanistic links between the biological clock and pathways underlying inflammatory arthritis, an animal model was developed where mice were administered collagen (or saline as a control) to induce arthritis. Furthermore, exposure of mice to constant light was carried to disrupt the clock in peripheral tissues, to record any loss of the nighttime repression of local inflammation.

The salient observations of the study were:
a: The treatment provoked an inflammatory response within the limbs, which showed robust daily variation in paw swelling and inflammatory cytokine expression.
b: Inflammatory markers were significantly repressed during the dark phase.
c: Exposure of mice to constant light disrupted the clock in peripheral tissues, causing loss of the nighttime repression of local inflammation.
Researchers attributed these findings to the ability of protein, called Cryptochrome, which have proven anti-inflammatory effects. Formed by the body's "biological clock" Cryptochrome actively represses inflammatory pathways within the affected limbs during the night.
To double check their findings, the researchers harvested cells from joint tissue of healthy mice called fibroblast-like synoviocytes (FLSs) which are important in the pathology that underlies inflammatory arthritis. Each of these cells keeps a 24-hour rhythm, and when this rhythm was disrupted by knocking out the cryptochrome gene there was an increased inflammatory response. This highlighted that importance of cryptochrome gene product of cryptochrome protein. To test this hypothesis, researchers administered drugs designed to activate the protein to determine if protection against inflammation could be achieved-and it was.
The authors conclude as “that under chronic inflammatory conditions, the clock actively represses inflammatory pathways during the dark phase. This interaction has exciting potential as a therapeutic avenue for treatment of inflammatory disease.”

Article citation: Gibbs, J. E.; et. al. The circadian clock regulates inflammatory arthritis. 2016, doi:10.1096/fj.201600353R

Friday, March 27, 2015

Drugs in Clinical Pipeline: Decernotinib

Decernotinib [(2R)-2-methyl-2-[[2-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl]amino]-N-(2,2,2-trifluoroethyl)butanamide] is an oral, selective Janus kinase 3 (JAK3) inhibitor. It is in Phase III  for the treatment of autoimmune and inflammatory diseases, including Rheumatoid Arthritis (RA).

In immune-mediated diseases, JAK3 is an essential component of the immune signaling cascade. This cascade ultimately contributes to abnormal immune response that results in chronic inflammation and, in the case of RA, irreversible damage to cartilage and bones.


IUPAC Name: (2R)-2-methyl-2-[[2-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl]amino]-N-(2,2,2-trifluoroethyl)butanamide
Common Name: VX-509; VRT-831509; Adelatinib
CAS No.: 944842-54-0
Originator: Vertex Pharmaceuticals


Monday, March 23, 2015

Biomarkers of Early Stage Osteoarthritis, Rheumatoid Arthritis

Biomarkers of Early Stage Osteoarthritis, Rheumatoid Arthritis 

Musculoskeletal disease including osteoarthritis (OA) and rheumatoid arthritis (RA) is the most common cause of chronic disability worldwide and is increasingly important in current ageing populations. Severe life impairment may be prevented if decline in musculoskeletal health and development of OA and RA are identified and treated in the early stages.

An inexpensive, minimally invasive biochemical test which preferably detects and distinguishes common types of arthritis at the early stage is required. Magnetic resonance imaging (MRI) techniques have been developed for early-stage evaluation of cartilage damage in OA. MRI is an expensive technique and also not favoured by all. Early biochemical tests for detection of established RA were based on measurement of rheumatoid factor (RF) which in current form have reported sensitivity and specificity of 63% and 94% respectively for established or advanced disease. RF is often negative with eRA. The anti-cyclic citrullinated peptide (CCP) antibody test is used for early-stage detection of RA and has sensitivity of 61%. 

There is currently no simple biochemical test to detect early-stage osteoarthritis (eOA) and to discriminate different types of early-stage arthritis.

Tests for early-stage rheumatoid arthritis (eRA) such as RF and CCP antibodies require refinement to improve clinical utility. Researchers have developed robust mass spectrometric methods to quantify citrullinated protein (CP) and free hydroxyproline (Hyp) in body fluids. On correlating CP in the plasma of healthy subjects it was surprisingly found that CP was increased in both patients with eOA and eRA whereas anti-CCP antibodies were predominantly present in eRA.

A 4-class diagnostic algorithm combining plasma/serum CP, anti-CCP antibody and hydroxyproline applied to a cohort gave specific and sensitive detection and discrimination of eOA, eRA, other non-RA inflammatory joint diseases and good skeletal health. This provides a first-in-class plasma/serum-based biochemical assay for diagnosis and type discrimination of early-stage arthritis to facilitate improved treatment and patient outcomes, exploiting citrullinated protein and related differential autoimmunity.
        
The clinical presence of anti-CCP antibodies, antibodies which bind to synthetic cyclic citrullinated peptide, are considered to reflect immunogenicity of endogenous citrullinated proteins (CPs) but the diagnostic utility of CPs has hitherto been little explored. 

The researchers hypothesized that changes in plasma CP and Hyp, combined with anti-CCP antibody test, would provide improved diagnostic power over current standard techniques for diagnosis of early-stage arthritis.


The surprising and remarkable biochemical finding of this study is increased levels of plasma CP in eOA. Increased CP was found in serum of eRA but this was suspected with regard to the high prevalence of anti-CCP antibody positivity in eRA. Also remarkable was the higher CP concentration in plasma than in synovial fluid of patients with eOA and reversal of this in patients with aOA. Autoimmunity to CP is important in the pathogenesis of RA and underlies the diagnostic utility of anti-CCP antibody measurement for eRA5. We found high levels of serum CP in patients with eRA and association of this with anti-CCP antibodies, consistent with formation and immunogenicity of CPs.

Article citation: Ahmed, U.; et. al. Biomarkers of early stage osteoarthritis, rheumatoid arthritis and musculoskeletal health. Scientific Reports, 2015, 5, Article number: 9259 doi:10.1038/srep09259

Thursday, March 12, 2015

Tofacitinib

Common name: Tofacitinib; CP-690550; CP-690550-10; Xeljanz; Jakvinus; Tofacitinib citrate
Trademarks: Xeljanz; Jakvinus
Molecular Formula: C16H20N6O 
CAS Registry Number: 477600-75-2; 540737-29-9(citrate)
CAS Name: 3-[(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanenitrile
Molecular Weight: 312.369
SMILES: C[C@@H]1CCN(C[C@@H]1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N
InChI Key: UJLAWZDWDVHWOW-YPMHNXCESA-N
InChI: InChI=1S/C16H20N6O/c1-11-5-8-22(14(23)3-6-17)9-13(11)21(2)16-12-4-7-18-15(12)19-10-20-16/h4,7,10-11,13H,3,5,8-9H2,1-2H3,(H,18,19,20)/t11-,13+/m1/s1
Activity: Treatment of Rheumatoid Arthritis; RA Treatment, JAK Inhibitor; Protein Kinase Inhibitor; JAK3 Inhibitor; Janus Kinase 3 Inhibitor; JAK-STAT Signaling Pathway; JAK1 Kinase Inhibitor; Selective Immunosuppressants
Status: Launched 2012
Originator: Pfizer

Tofacitinib synthesis: US2001053782A1

Tofacitinib synthesis: WO2002096909A1

Tofacitinib synthesis: Org Process Res Dev 201418(12), 1714-1720 (also from a chinese publication, same procedure just slight changes in reagents/conditions)

References:
1. Blumenkopf, T. A.; et. al. Pyrrolo[2,3-d]pyrimidine compounds. US2001053782A1
2. Flanagan, M. E.; et. al. Optical resolution of (1-benzyl-4-methylpiperidin-3-yl) -methylamine and the use thereof for the preparation of pyrrolo 2,3-pyrimidine derivatives as protein kinases inhibitors. WO2002096909A1
3. Das, A.; et. al. An Improved and Efficient Process for the Preparation of Tofacitinib Citrate. Org Process Res Dev 2014, 18(12), 1714-1720.

For more drugs and their synthesis: Synayurajan database